Skin Boosters and Injectable Moisturizers

Skin boosters occupy a category of their own: injectables developed to improve intrinsic skin quality, such as hydration and tone, without the volumetric correction expected of traditional fillers. Yet the category is used less often than neuromodulators, hyaluronic acid (HA) gel filler, or biostimulatory filler, typically added on rather than offered as a singular treatment. Low-concentration, small-particle HA formulations such as SkinVive (VYC-12L, Allergan Aesthetics) anchor this category, along with polydeoxyribonucleotide (PDRN) and platelet-rich plasma (PRP), each acting through distinct biological mechanisms with different levels of clinical support and, as detailed below, very different regulatory standing in the United States. In the pivotal VYC-12L trial, the proportion of patients satisfied with their facial skin smoothness rose from 19.1% at baseline to 79.5% at 1 month post-treatment.¹ In my practice, I utilize skin boosters in several ways: pairing them with laser and energy-based devices, correcting shadowing on the lateral cheeks, and as a standalone option for patients who are not candidates for, or not interested in, volumizing filler.

WHAT IS FDA-APPROVED AND AVAILABLE IN THE US? 

The regulatory picture matters more here than in most in jectable categories. SkinVive is the only US Food and Drug Administration (FDA)-approved HA skin booster in the US, with two indications: improvement of cheek skin smoothness since 2023, and improvement of neck appearance, including horizontal neck lines, since June 2026.² The neck clinical trial found that 74.8% of participants achieved clinically meaningful improvement on the Allergan Transverse Neck Lines Scale at 1 month, with durability sustained through month 6. The US Food and Drug Administration (FDA) has required an injector training program prior to purchase and administration. 

No injectable PDRN product is FDA-approved currently for aesthetic use in the US. The material is cleared for cosmetic injection in South Korea and parts of Europe under different regulatory frameworks, but it is not legally available here as a labeled aesthetic injectable. PRP, meanwhile, is not itself an FDA-approved drug; rather, it is an autologous biologic prepared using FDA-cleared processing kits and administered off-label for skin rejuvenation at physician discretion. Any PRP protocol discussed in the literature, including in this review, should be understood as off-label or investigational in the US context, and represented to patients as such.

THE DATA BEHIND THE CATEGORY

When injected in microdroplet fashion, intradermal HA addresses dermal hydration while also stimulating fibroblast activity and upregulating type I and III collagen and elastin expression.³ An expert panel consensus on non-animal stabilized HA (NASHA)-based skin boosters established the treatment framework: an initial series of up to 3 sessions, followed by maintenance every 4 to 6 months, with texture improvement detectable for up to a year of repeat treatment.⁴ The VYC-12L cheek trial (n=202) demonstrated Allergan Cheek Smoothness Scale responder rates of 57.9% versus 4.5% for untreated controls at 1 month, sustained through month 5.⁵ This combination of a documented biostimulatory effect and durability is why I view skin boosters as a distinct category rather than a hydration add-on.

PAIRING SKIN BOOSTERS WITH ENERGY-BASED DEVICES 

I routinely perform a skin booster treatment at the same visit as fractional laser resurfacing or another energy-based treatment. The rationale is twofold. In the short term, intradermal HA offsets the transient barrier disruption that follows fractional laser resurfacing, mitigating post-procedure erythema. A 2025 global expert consensus on integrating VYC-12L with energy-based devices supports this combination directly, outlining sequencing and technique considerations for safe, effective same-day treatment.⁶ Histologic studies evaluating fractional lasers and energy-based devices on intradermally injected HA further suggest that fractionated channels may enhance dispersion of the HA within the dermis.⁷ A split-face randomized controlled trial pairing onabotulinumtoxinA with VYC-12L for periorbital wrinkles found significantly greater improvement than toxin alone. Though this combination differs from pairing with laser treatment, it demonstrates the same underlying principle: layering a skin booster with a complementary treatment compounds results.⁸

The longer-term rationale is that both energy-based devices and intradermal HA independently stimulate fibroblast-driven collagen synthesis. Combining these treatments appears to produce a more sustained remodeling response than either alone. I have not studied this as a controlled comparison in my own patients, and the pairing extends beyond current FDA labeling, but it has become one of the more reliable ways that I improve both the immediate post-laser experience and the durability of the result.

ADDRESSING SKIN TONE

A frequent cosmetic concern among patients with Fitzpatrick IV to VI is submalar shadowing or hyperpigmentation. In these cases, there is not a true volume deficit but rather bone structure and melanin density combining to create a visual hollow. Traditional HA filler placed in this region has the risk of overcorrection and an imbalanced look of which our patients are increasingly wary. Microdroplet HA placed superficially in this zone changes how light reflects off the skin surface without adding meaningful volume (Figures 1 and 2). This is a clinical observation rather than a trial-supported indication specific to skin of color, and I encourage colleagues who adopt it to document outcomes carefully. It has nonetheless become a requested treatment among my patients with deeper skin tones who want the shadow addressed without a change to their facial contour.

Figures 1 and 2. Before-and-after photographs of a patient who received 3 syringes of microdroplet HA 6 weeks apart for overall improvement of skin tone.

A STANDALONE OPTION FOR SKIN QUALITY 

Skin quality is enjoying a resurgence of its own, as patients increasingly prioritize it alongside volume correction. Skin boosters address that need directly, nearly quadrupling satisfaction with facial skin smoothness from baseline to 1 month in the pivotal trial.¹ Skin boosters are demonstrated to measurably improve hydration, elasticity, and tone independent of any volumizing effect.^4,5 For patients wary of volumizing fillers, a standalone treatment can deliver improvement in skin quality while maintaining that no structural change is intended.

TECHNIQUE AND SAFETY 

Intradermal microdroplet technique and depth matter more than volume. Injection into the subcutaneous plane bypasses the surface effect of skin boosters. I use a fanning, serial-puncture technique with careful depth control. I counsel patients on the small but real risk of transient bruising and, less commonly, nodule formation if product is placed too superficially. For submalar shadowing, I stage treatments in an effort to minimize risk of overcorrection. In older patients, I find that more sessions, often more than two syringes total, are needed to achieve the same effect as in younger patients (Figures 3 and 4).

Figures 3 and 4. An older patient who received 4 syringes of microdroplet HA over 2 visits spaced 4 weeks apart for submalar hyperpigmentation.

WHERE EVIDENCE STANDS

Compared with PDRN and PRP, HA-based skin boosters carry the more standardized clinical evidence from multicenter randomized controlled trials, as well as reproducible outcomes across independent trials. PDRN has strong mechanistic and wound-healing data but limited high-quality clinical trials, with no current pathway to FDA-approved injectable use in the US.⁹ PRP shows moderate, heterogeneous evidence, stronger for skin thickness and elasticity, but not as strong for hydration, and remains an off-label application of an autologous product.¹⁰ The applications described here—pairing with energy devices, correcting lateral cheek shadowing, and standalone use—extend beyond current labeled indications and should be represented to patients as such. In practice, skin boosters now function as another pillar of injectable treatment, alongside neuromodulator and filler, addressing skin quality directly.